Search research articles
Contact Us
Filters
Showing results (441-450 of 459) with videos related to
Page
of 46
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 2014
Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma
Carrie A Thompson, Herve Ghesquieres, Matthew J Maurer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 15, 2017
Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial
Marc P E André, Théodore Girinsky, Massimo Federico, et al.
Blood
|
January 25, 2020
High total metabolic tumor volume at baseline predicts survival independent of response to therapy
Laetitia Vercellino, Anne-Segolene Cottereau, Olivier Casasnovas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 21, 2017
Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Catherine Thieblemont, Hervé Tilly, Maria Gomes da Silva, et al.
Angewandte Chemie (International Ed. in English)
|
July 8, 2025
Designing New Natural-Mimetic Phosphatidic Acid: A Versatile and Innovative Synthetic Strategy for Glycerophospholipid Research
Antoine Schlichter, Alexander Wolf, Thomas Ferrand, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 30, 2017
Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy
Emanuele Zucca, Annarita Conconi, Giovanni Martinelli, et al.
Blood
|
August 19, 2011
Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma
Philippe Moreau, Herve Avet-Loiseau, Thierry Facon, et al.
Haematologica
|
April 15, 2014
Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients
Marie-Lorraine Chretien, Benjamin Hebraud, Valérie Cances-Lauwers, et al.
Leukemia
|
July 30, 2013
Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients
B Hebraud, X Leleu, V Lauwers-Cances, et al.
American Journal of Hematology
|
July 29, 2016
Early event status informs subsequent outcome in newly diagnosed follicular lymphoma
Matthew J Maurer, Emmanuel Bachy, Hervé Ghesquières, et al.
Page
of 46
Search research articles
Search
Showing results (441-450 of 459) with videos related to
Sort By:
Page
of 46
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 2014
Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma
Carrie A Thompson, Herve Ghesquieres, Matthew J Maurer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 15, 2017
Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial
Marc P E André, Théodore Girinsky, Massimo Federico, et al.
Blood
|
January 25, 2020
High total metabolic tumor volume at baseline predicts survival independent of response to therapy
Laetitia Vercellino, Anne-Segolene Cottereau, Olivier Casasnovas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 21, 2017
Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Catherine Thieblemont, Hervé Tilly, Maria Gomes da Silva, et al.
Angewandte Chemie (International Ed. in English)
|
July 8, 2025
Designing New Natural-Mimetic Phosphatidic Acid: A Versatile and Innovative Synthetic Strategy for Glycerophospholipid Research
Antoine Schlichter, Alexander Wolf, Thomas Ferrand, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 30, 2017
Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy
Emanuele Zucca, Annarita Conconi, Giovanni Martinelli, et al.
Blood
|
August 19, 2011
Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma
Philippe Moreau, Herve Avet-Loiseau, Thierry Facon, et al.
Haematologica
|
April 15, 2014
Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients
Marie-Lorraine Chretien, Benjamin Hebraud, Valérie Cances-Lauwers, et al.
Leukemia
|
July 30, 2013
Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients
B Hebraud, X Leleu, V Lauwers-Cances, et al.
American Journal of Hematology
|
July 29, 2016
Early event status informs subsequent outcome in newly diagnosed follicular lymphoma
Matthew J Maurer, Emmanuel Bachy, Hervé Ghesquières, et al.
Page
of 46